Vanda Pharmaceuticals Inc. [NASDAQ: VNDA] stock went on an upward path that rose over 21.16% on Thursday, amounting to a one-week price increase of more than 29.65%. The company report on February 11, 2021 that Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results.
– Q4 2020 total revenues grew to $67.7 million, an 11% increase compared to Q4 2019.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
– Full year 2020 total revenues grew to $248.2 million, a 9% increase compared to 2019.
Over the last 12 months, VNDA stock rose by 41.55%. The one-year Vanda Pharmaceuticals Inc. stock forecast points to a potential downside of -16.69. The average equity rating for VNDA stock is currently 2.00, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $969.91 million, with 54.67 million shares outstanding and 52.91 million shares in the current float. Compared to the average trading volume of 438.11K shares, VNDA stock reached a trading volume of 4096740 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Vanda Pharmaceuticals Inc. [VNDA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for VNDA shares is $16.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on VNDA stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Citigroup have made an estimate for Vanda Pharmaceuticals Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on January 14, 2021. The new note on the price target was released on October 29, 2020, representing the official price target for Vanda Pharmaceuticals Inc. stock. Previously, the target price had yet another raise to $14, while Citigroup analysts kept a Neutral rating on VNDA stock.
The Average True Range (ATR) for Vanda Pharmaceuticals Inc. is set at 0.87, with the Price to Sales ratio for VNDA stock in the period of the last 12 months amounting to 4.02. The Price to Book ratio for the last quarter was 2.32, with the Price to Cash per share for the same quarter was set at 6.71. Price to Free Cash Flow for VNDA in the course of the last twelve months was 23.43 with Quick ratio for the last quarter at 6.30.
VNDA Stock Performance Analysis:
Vanda Pharmaceuticals Inc. [VNDA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 29.65. With this latest performance, VNDA shares gained by 31.85% in over the last four-week period, additionally plugging by 57.02% over the last 6 months – not to mention a rise of 41.55% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for VNDA stock in for the last two-week period is set at 82.63, with the RSI for the last a single of trading hit 87.50, and the three-weeks RSI is set at 78.42 for Vanda Pharmaceuticals Inc. [VNDA]. The present Moving Average for the last 50 days of trading for this stock 13.95, while it was recorded at 16.07 for the last single week of trading, and 11.81 for the last 200 days.
Insight into Vanda Pharmaceuticals Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Vanda Pharmaceuticals Inc. [VNDA] shares currently have an operating margin of +10.04 and a Gross Margin at +88.56. Vanda Pharmaceuticals Inc.’s Net Margin is presently recorded at +50.86.
Return on Total Capital for VNDA is now 6.51, given the latest momentum, and Return on Invested Capital for the company is 33.07. Return on Equity for this stock inclined to 33.67, with Return on Assets sitting at 28.33. When it comes to the capital structure of this company, Vanda Pharmaceuticals Inc. [VNDA] has a Total Debt to Total Equity ratio set at 3.55. Additionally, VNDA Total Debt to Total Capital is recorded at 3.43, with Total Debt to Total Assets ending up at 3.02. Long-Term Debt to Equity for the company is recorded at 3.03, with the Long-Term Debt to Total Capital now at 2.93.
Reflecting on the efficiency of the workforce at the company, Vanda Pharmaceuticals Inc. [VNDA] managed to generate an average of $406,877 per employee. Receivables Turnover for the company is 8.24 with a Total Asset Turnover recorded at a value of 0.56.Vanda Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.30 and a Current Ratio set at 6.30.
VNDA Stock EPS
With the latest financial reports released by the company, Vanda Pharmaceuticals Inc. posted 0.01/share EPS, while the average EPS was predicted by analysts to be reported at 0/share. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for VNDA.
Vanda Pharmaceuticals Inc. [VNDA] Insider Position Details
There are presently around $1,030 million, in the hands of institutional investors. The top three institutional holders of VNDA stocks are: BLACKROCK INC. with ownership of 9,814,597, which is approximately 5.782% of the company’s market cap and around 2.80% of the total institutional ownership; ARMISTICE CAPITAL, LLC, holding 5,450,000 shares of the stock with an approximate value of $83.98 million in VNDA stocks shares; and PALO ALTO INVESTORS LP, currently with $64.26 million in VNDA stock with ownership of nearly 1.305% of the company’s market capitalization.
Positions in Vanda Pharmaceuticals Inc. stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 88 institutional holders increased their position in Vanda Pharmaceuticals Inc. [NASDAQ:VNDA] by around 4,951,491 shares. Additionally, 80 investors decreased positions by around 5,455,926 shares, while 30 investors held positions by with 44,767,531 shares. The mentioned changes placed institutional holdings at 55,174,948 shares, according to the latest SEC report filing. VNDA stock had 31 new institutional investments in for a total of 1,796,456 shares, while 22 institutional investors sold positions of 787,613 shares during the same period.